Diagnosis and Treatment of Painful Diabetic Peripheral Neuropathy
- PMID: 35544662
- Bookshelf ID: NBK580224
- DOI: 10.2337/db2022-01
Diagnosis and Treatment of Painful Diabetic Peripheral Neuropathy
Excerpt
Diabetic neuropathies are the most common chronic complications of diabetes, with an estimated lifetime prevalence exceeding 50% in people with diabetes. Among various forms of neuropathy, diabetic peripheral neuropathy (DPN) is the most common and has the strongest evidence base regarding therapeutic approaches. This American Diabetes Association clinical compendium summarizes the latest information about screening for, diagnosing, and treating painful DPN in routine clinical practice. It opens with an overview of the epidemiology of DPN, followed by a description of the pathophysiology of the disease and its often severely painful symptoms. The authors recommend a stepwise approach to effectively diagnose DPN and offer a novel perspective on the impact of social determinants of health on the development and management of DPN. They summarizes the latest guidance on effective therapies, including pharmacological oral and topical agents, nutraceutical products, and nonpharmacological therapies, including physical activity and dietary interventions, passive modalities, and energy or nerve stimulation techniques. Throughout the publication, the authors identify knowledge gaps that need to be addressed and advocate a personalized care approach to reduce the burden of painful DPN and optimize quality of life for individuals affected by it.
© 2022 by American Diabetes Association. All rights reserved. None of the contents may be reproduced without the written permission of the American Diabetes Association.
Conflict of interest statement
R.P.-B. has served on advisory boards for Averitas Pharma, Boehringer Ingelheim, Novo Nordisk, and Nevro.
D.Z. has served as a consultant to Allergan, Bayer, Berlin-Chemie, Biogen, Cannaxan, Clexio, Grünenthal, Mitsubishi Tanabe, Mundipharma, Nevro, Novaremed, Novartis, Pathways Public Health, Pfizer, Procter & Gamble, Stada, Takeda, Viatris, and Wörwag; he has been a speaker for Astellas, AstraZeneca, Berlin-Chemie, Mundipharma, Pfizer, Sanofi, Takeda, Viatris, and Wörwag; and he has received research support from Mitsubishi Tanabe, Novartis, and Wörwag.
No other potential conflicts of interest relevant to this work were reported.
Similar articles
-
The conundrum of diabetic neuropathies-Past, present, and future.J Diabetes Complications. 2022 Nov;36(11):108334. doi: 10.1016/j.jdiacomp.2022.108334. Epub 2022 Oct 7. J Diabetes Complications. 2022. PMID: 36306721 Free PMC article. Review.
-
Pharmacological and Nonpharmacological Treatments for Painful Diabetic Peripheral Neuropathy.Diabetes Metab J. 2023 Nov;47(6):743-756. doi: 10.4093/dmj.2023.0018. Epub 2023 Sep 6. Diabetes Metab J. 2023. PMID: 37670573 Free PMC article. Review.
-
The Treatment of Painful Diabetic Neuropathy.Curr Diabetes Rev. 2022;18(5):e070721194556. doi: 10.2174/1573399817666210707112413. Curr Diabetes Rev. 2022. PMID: 34238163 Review.
-
Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management.Diabetes Metab Res Rev. 2011 Oct;27(7):629-38. doi: 10.1002/dmrr.1225. Diabetes Metab Res Rev. 2011. PMID: 21695762
-
Female sex is a risk factor for painful diabetic peripheral neuropathy: the EURODIAB prospective diabetes complications study.Diabetologia. 2024 Jan;67(1):190-198. doi: 10.1007/s00125-023-06025-z. Epub 2023 Oct 23. Diabetologia. 2024. PMID: 37870649 Free PMC article.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources